Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:39 AM
Ignite Modification Date:
2025-12-25 @ 12:39 AM
NCT ID:
NCT05961267
Brief Summary:
Autoimmune diseases are the consequence of an abnormality of the immune system, leading it to attack components of our own body. They have a wide variety of presentations. They preferentially affect women, and often at a young age. Systemic lupus erythematosus, for example, most often occurs between the ages of 15 and 40.
Inflammatory rheumatism, such as spondyloarthritis or rheumatoid arthritis, is less prevalent in women, but also affects young people, and is particularly common.
Several disease-modifying treatments exist, depending on the severity and evolutivitý of the disease. Some are contraindicated or not recommended during pregnancy and therefore require supervision of pregnancy plans.
In addition, some treatments have an immunosuppressive activitý, which implies an annual screening of cervical lesions by cervico-uterine smear.
In this context, an adapted gynecological follow-up seems indispensable. The rheumatologist and the internist physician have a crucial role in advising and referring patients to their gynecological colleagues.
Studying the qualitý of this gynecological follow-up in a cohort of patients with autoimmune disease or inflammatory rheumatism is of major interest.
Detailed Description:
To evaluate the gynecological follow-up of patients with autoimmune diseases or inflammatory rheumatism by:
* Assessing the proportion of patients reporting having contraception described as effective by guidelines within one year in the study population.
* Evaluating the proportion of patients reporting having had a consultation for screening or follow-up for cervical dysplasia in the year.
Descriptive analysis of :
* Factors associated with effective contraceptive use and frequency of cervical smear screening.
* The impact of the disease on the pregnancy project.
* The appropriateness of the chosen contraceptive and the patients' comorbidities.
* The prevalence of Human Papillomavirus (HPV) infections, cervical dysplasia, cervical cancer in this French population at risk.
* Barriers to gynecological care.
Study:
NCT05961267
Study Brief:
Protocol Section:
NCT05961267